Pheton (NASDAQ:PTHL) and Bausch + Lomb (NYSE:BLCO) Head-To-Head Contrast

Pheton (NASDAQ:PTHL) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Pheton and Bausch + Lomb, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
Bausch + Lomb	1	9	4	0	2.21

Bausch + Lomb has a consensus price target of $17.92, indicating a potential upside of 18.77%. Given Bausch + Lomb’s stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Pheton.

Valuation & Earnings

This table compares Pheton and Bausch + Lomb”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305,215.00	8.73	-$660,000.00	N/A	N/A
Bausch + Lomb	$5.10 billion	1.06	-$360.00 million	($0.62)	-24.33

Pheton has higher earnings, but lower revenue than Bausch + Lomb.

Profitability

This table compares Pheton and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Bausch + Lomb	-4.21%	3.60%	1.69%

Insider & Institutional Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bausch + Lomb beats Pheton on 8 of the 12 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.